JOURNAL OF EXPERIMENTAL ZOOLOGY (MOL DEV EVOL) 312B:445–457 (2009)
Amelogenin in Cranio-facial Development: The
Tooth as a Model to Study the Role of Amelogenin
During Embryogenesis
YAEL GRUENBAUM-COHEN1, ABIGAIL S. TUCKER2, AMIR HAZE1,
DEKEL SHILO1, ANGELA L. TAYLOR1, BOAZ SHAY1, PAUL T. SHARPE2,
THIMIOS A. MITSIADIS3, ASHER ORNOY4, ANAT BLUMENFELD1, AND
DAN DEUTSCH1
1
Dental Research Laboratory, Institute of Dental Sciences, Hebrew University,
Hadassah, Faculty of Dental Medicine, Jerusalem, Israel
2
Department of Craniofacial Development, Dental Institute, King’s College,
Guy’s Campus, London, England
3
Institute for Oral Biology, Department of Orofacial and Structural Biology,
University of Zurich, Faculty of Medicine, Zurich, Switzerland
4
Laboratory of Teratology, Department of Anatomy and Cell Biology, Hebrew
University—Hadassah Medical School, Jerusalem, Israel
ABSTRACT
The amelogenins comprise 90% of the developing extracellular enamel matrix
proteins and play a major role in the biomineralization and structural organization of enamel.
Amelogenins were also detected, in smaller amounts, in postnatal calcifying mesenchymal tissues,
and in several nonmineralizing tissues including brain. Low molecular mass amelogenin isoforms
were suggested to have signaling activity; to produce ectopically chondrogenic and osteogenic-like
tissue and to affect mouse tooth germ differentiation in vitro. Recently, some amelogenin isoforms
were found to bind to the cell surface receptors; LAMP-1, LAMP-2 and CD63, and subsequently
localize to the perinuclear region of the cell. The recombinant amelogenin protein (rHAM1) alone
brought about regeneration of the tooth supporting tissues: cementum, periodontal ligament and
alveolar bone, in the dog model, through recruitment of progenitor cells and mesenchymal stem cells.
We show that amelogenin is expressed in various tissues of the developing mouse embryonic
cranio-facial complex such as brain, eye, ganglia, peripheral nerve trunks, cartilage and bone, and is
already expressed at E10.5 in the brain and eye, long before the initiation of tooth formation.
Amelogenin protein expression was detected in the tooth germ (dental lamina) already at E13.5,
much earlier than previously reported (E19). Application of amelogenin (rHAM1) beads together
with DiI, on E13.5 and E14.5 embryonic mandibular mesenchyme and on embryonic tooth germ,
revealed recruitment of mesenchymal cells. The present results indicate that amelogenin has an
important role in many tissues of the cranio-facial complex during mouse embryonic development
and differentiation, and might be a multifunctional protein. J. Exp. Zool. (Mol. Dev. Evol.)
r 2008 Wiley-Liss, Inc.
312B:445– 457, 2009.
How to cite this article: Gruenbaum-Cohen Y, Tucker AS, Haze A, Shilo D, Taylor AL,
Shay B, Sharpe PT, Mitsiadis TA, Ornoy A, Blumenfeld A, Deutsch D. 2009. Amelogenin in
cranio-facial development: the tooth as a model to study the role of amelogenin during
embryogenesis. J. Exp. Zool. (Mol. Dev. Evol.) 312B:445–457.
The amelogenins, which comprise about 90% of
the enamel matrix proteins (Termine et al., ’80),
play a major role in the biomineralization and
structural organization of enamel (Robinson et al.,
’88; Fincham et al., ’94). Amelogenins are hydrophobic molecules that self-assemble in vitro and in
vivo into nanospheric structures, which regulate
r 2008 WILEY-LISS, INC.
Grant sponsor: Israel Science Foundation (ISF); Grant number:
597/02.
Correspondence to: Dan Deutsch, Head, Dental Research Laboratory, Institute of Dental Sciences, Hebrew University, Hadassah,
Faculty of Dental Medicine, Jerusalem 91120, Israel.
E-mail: dddan@cc.huji.ac.il
Received 13 November 2008; Accepted 14 November 2008
Published online 18 December 2008 in Wiley InterScience (www.
interscience.wiley.com). DOI: 10.1002/jez.b.21255
446
Y. GRUENBAUM-COHEN ET AL.
the oriented and elongated growth, shape and size
of the enamel mineral crystal (Fincham et al., ’94;
Du et al., 2005; Veis, 2005). During enamel
development and mineralization, the amelogenins
in the extracellular enamel are sequentially and
discretely degraded by specific proteases the
metalloprotease Enamelysin (MMP20) and the
serine protease KLK4 (Simmer and Hu, 2002).
The amelogenins are eventually, together with
other enamel matrix proteins, replaced by mineral
ions calcium and phosphorus, the enamel finally
becoming hard, fully mineralized (96%) and
mature (Termine et al., ’80; Deutsch et al., ’95;
Robinson et al., ’98).
The mouse amelogenin gene is mapped to the X
chromosome (Lau et al., ’89; Fincham et al., ’91),
whereas in the human it maps to Xp22.1–p22.3
and Yp11.2 chromosomes (Lau et al., ’89; Salido
et al., ’92). The gene contains nine exons (Li et al.,
’98; Baba et al., 2002) that undergo extensive
alternative mRNA splicing (Simmer and Fincham,
’95; Veis, 2003; Papagerakis et al., 2005). The most
abundant amelogenin isoform in the mouse
enamel is M180 that is encoded by exons 1–7,
skipping exon 4.
In human, mutations in the X-chromosomal
copy of the amelogenin gene AMELX have been
associated with the hereditary disease Amelogenesis Imperfecta (Hart et al., 2000). Defective
enamel formation has also been demonstrated by
knockdown of amelogenin expression using antisense oligonucleotides (Diekwisch et al., ’93),
ribozymes (Lyngstadaas et al., ’95) and in amelogenin knockout and transgenic mice, which resulted in enamel characteristic of hypoplastic
amelogenesis imperfecta, with reduced enamel
thickness (Gibson et al., 2001).
For decades amelogenin was thought to be
exclusively an enamel (epithelial origin) protein.
However, in more recent years different isoforms
of amelogenin have also been found in the dentin
matrix (Hammarstrom et al., ’97; Nebgen et al.,
’99) and the odontoblasts (Oida et al., 2002;
Papagerakis et al., 2003), during cementogenesis
in remnants of Hertwig’s root sheath and in
periodontal ligament (PDL) cells (Fong and
Hammarstrom, 2000; Janones et al., 2005). Very
recently, we have described amelogenin expression in long bone cells; osteocytes, osteoblasts and
osteoclasts, and some of the bone marrow cells.
Amelogenin is also expressed in chondrocytes of
the articular cartilage and differentially in cell
layers of the epiphyseal growth plate. We have
identified amelogenin expression in long bone
J. Exp. Zool. (Mol. Dev. Evol.)
marrow cells, some of which are mesenchymal
stem cells, and in cells surrounding blood vessels
(Haze et al., 2007). Amelogenin expression was
also identified in cells of nonmineralizing tissues
such as the brain, specifically in the glial cells, in
salivary glands and in some of the hematopoietic
cells such as megakaryocytes and macrophage
(Deutsch et al., 2006; Haze et al., 2007). The
relatively large number of amelogenin alternatively spliced mRNA translated polypeptides and
the fact that amelogenin is expressed in different
tissues (calcifying and soft tissues) and of different
embryonic origin, possibly reflect different functions of amelogenin.
Low molecular mass amelogenin isoforms were
suggested to be signal molecules; were shown to
produce ectopically chondrogenic and osteogeniclike tissue and to have different signaling effects
on ameloblasts and odontoblasts differentiation in
developing tooth culture model, and when implanted in the tooth pulp (Nebgen et al., ’99; Veis,
2003; Lacerda-Pinheiro et al., 2006a,b; ZeichnerDavid et al., 2006; Jegat et al., 2007). Amelogenin
(M180), the amelogenin isoform LRAP (leucinrich amelogenin peptide), and some of the amelogenin degradation products, were found to bind to
the cell surface receptors; LAMP-1, LAMP-2 and
CD63, which are ubiquitously expressed lysosomal
integral membrane proteins that are also localized
to the plasma membrane. Shapiro et al. found that
exogenously added amelogenin moves rapidly into
established LAMP-1 positive vesicles that subsequently localize to the perinuclear region of the
cell (Shapiro et al., 2007). Zou et al. reported the
exact regions and sequences that bind amelogenin
to these receptors (Zou et al., 2007).
A major discovery that highlights a new role for
enamel matrix proteins was the finding that the
application of an enamel matrix protein extract to
tooth root surfaces in sites of diseased periodontium promotes the regeneration of all the
periodontal tissues (Hammarstrom et al., ’97). It
was therefore suggested that amelogenin is responsible for this regeneration. Recently, we
showed that the recombinant human amelogenin
protein (rHAM1), produced in the eukaryotic
baculovirus system (Taylor et al., 2006), causes
significant and progressive regeneration of all
three tooth supporting tissues; alveolar bone,
PDL and cementum, after induction of chronic
periodontitis, in the dog. Further immunohistochemistry studies, using markers for mesenchymal stem cells, combined with the above findings,
suggested that amelogenin induces, directly or
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
indirectly, recruitment of mesenchymal stem cells
and/or progenitor cells, during the regeneration of
the tooth supporting tissues (Deutsch et al., 2006).
Large amount of information is available in the
literature on genes and their corresponding
proteins, associated with embryonic tooth development, morphogenesis and differentiation, such
as signaling molecules, growth factors, homeoboxes etc. (Tucker and Sharpe, ’99; Jernvall and
Thesleff, 2000; Tucker and Sharpe, 2004; Hu
et al., 2006; Mitsiadis and Smith, 2006). The same
is true for all other cranio-facial organs. However,
almost no data is available on amelogenin expression and function in the early stages of embryonic
cranio-facial development.
In this study we focused on the spatio-temporal
expression of amelogenin in different tissues of the
developing embryonic mouse cranio-facial complex, such as the tooth germ, brain, eye, ganglia,
peripheral nerve trunks, cartilage and bone. Our
results indicate that amelogenin is expressed in
many tissues of the cranio-facial complex during
mouse embryonic development and differentiation, pointing to the possibility that it might be a
multifunctional protein.
RESULTS
Amelogenin mRNA expression in the
cranio-facial complex during mouse
embryonic days E10.5– E17.5
The expression of amelogenin mRNA, in the
cranio-facial complex at E10.5 up to E17.5, was
analyzed by RT-PCR, followed by cDNA sequencing (Fig. 1A). The most abundant amelogenin
isoform in the extracellular enamel matrix, M180
(exons 1–7 lacking exon 4, Fig. 1B), was detected
along the different stages of mouse embryonic
cranio-facial development. Other amelogenin isoforms might also be present. We are currently
looking for such isoforms.
Spatio-temporal expression of amelogenin
in the cranio-facial complex during E10.5E18.5 mouse embryonic development
(Fig. 2)
Amelogenin expression (red brown staining) was
detected in different tissues of the mouse embryonic cranio-facial complex, at different stages of
development. No staining was observed in the
corresponding control (PBS) sections (not shown).
447
Fig. 1. (A) Expression of amelogenin cDNA isoform M180
in the mouse embryonic cranio-facial complex at E10.5
through E17.5. (B) Schematic representation of the exon
structure of M180.
Amelogenin expression in the developing
eye (Fig. 2a)
At E10.5 positive staining for amelogenin was
detected at the outer peripheral area of the inner
part of the optic cup (OC), which gives rise to the
photoreceptors. At E11.5 staining in the area of
the photoreceptors (Pr) facing the future pigment
epithelium region, was more intense. At E12.5,
faint staining was also detected in fibers at the
inner side of the optic nerve, with the precursors
of the photoreceptors (Pr) being more intensely
stained. Cells at the periphery of the lens stained
positively, as well as the lens fibers. In the
epithelium that will develop into the cornea few
cells were positively stained (Cr). At E13.5, the
fibers, connective tissue and choroidal blood
vessels (Ch) were positively stained, while still
few cells in the cornea (Cr) were stained. At E14.5
lens fibers (LF) were positively stained, and faint
staining was detected in most of the cornea (Cr)
cells, as well as in the sclera (Sc). Staining was also
observed in the vitreous (Vi) but not in the retina
(Re), as the photoreceptors loose their staining. At
E15.5 the lining epithelium at the anterior part of
the lens, as well as the retina (Re), did not stain,
whereas the choroidal blood vessels stained positively (Ch). At E16.5 mainly lens fibers (LF) and
the entire choroid (Ch) was positively stained. In
the ganglion layer (GC) of the retina (Re), cell
bodies (cytoplasm) and fibers were stained, but at
that stage the bipolar cell layer, the photoreceptors and the pigment epithelium did not stain with
amelogenin antibodies. At E18.5 the lens (LF) was
completely stained. The retinal vessels and the
sub-epithelial areas (EI) over the eyelids were also
stained
Amelogenin expression in the developing
brain (Fig. 2a)
At E10.5 positive staining for amelogenin
was detected in the cranial part of the
neural tube at the external limiting membrane
(ELM), where glial cells were stained. When fibers
were detected—they apparently also stained for
J. Exp. Zool. (Mol. Dev. Evol.)
448
Fig. 2. Contined.
J. Exp. Zool. (Mol. Dev. Evol.)
Y. GRUENBAUM-COHEN ET AL.
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
449
Fig. 2. Spatio-temporal distribution of amelogenin expression in tissues of E10.5–E18.5 mouse embryonic cranio-facial
complex (Amelogenin expression—brown red staining, hematoxylin—blue staining). Eye: Ch—choroidal blood vessels; Cr—
cornea; EI—sub-epithelial region; GC—ganglion layer; LF—lens fibers; OC—optic cup; Pr—photoreceptors; Re—retina;
Sc—sclera; Vi—vitreous. Brain: C—cortex; CP—cortical plate; ELM—external limiting membrane; LV—lateral ventricle; MB—
midbrain; P—pons; Tc—telencephalon; TCr—temporal cortex TL—temporal lobe. Peripheral nerve trunk: NF—peripheral
nerve fibers. Tooth germ: Ab—ameloblasts; Av—alveolar bone trabecules; CL—cervical loop; D—dentin; DL—dental lamina;
DP—dental papilla; EM—extracellular enamel matrix; IEE—inner enamel epithelium; Od—odontoblasts; OEE—outer enamel
epithelium; PD—pre-dentin; SI—stratum intermedium; SR—stellate reticulum; TG—tooth germ. Cartilage: DC—differentiated
chondrocytes; HC—Hypertrophic cartilage; Pc—Pre-chondrocytes; WDC—well developed chondrocytes. Bone: BT—bone
trabecules. (A) In the eye, brain and peripheral nerve trunk at E10.5, E11.5, E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5. (B) In
the tooth germ, cartilage, bone and ganglion at E12.5, E13.5, E14.5, E15.5, E16.5 and E18.5. No amelogenin staining was
detected in the corresponding control (PBS) sections (not shown).
amelogenin. Most of the staining in the nerve
fibers was probably associated with the glial cells,
however, it is not clear whether some axons or
dendrites were also stained. At E11.5 amelogenin
expression was detected in the anterior (ventral)
regions of the midbrain (MB), mainly in fiber-like
structures and glial cells. Staining was also
observed in the tissue that will eventually develop
into cartilage at the base of the skull. At E12.5
positive, but weak, amelogenin staining was
J. Exp. Zool. (Mol. Dev. Evol.)
450
Y. GRUENBAUM-COHEN ET AL.
detected in the medial part (that is rich in fibers)
of the telencephalon (Tc), whereas no staining was
detected in the cortical plate (CP), which, at that
stage comprised mainly of neuroblasts. In general,
amelogenin staining was observed in both brain
hemispheres in fiber-like structures. In most
cases, the glial cells stained positively, but other
cell types (neurons) might also be involved. At
E13.5, fibers (white material under the cortical
plate) stained positively whereas no staining was
detected in the cortical neurons. At E14.5 dispersed positive staining of glial cells throughout
the brain especially in the midbrain (MB) and
pons (P), and not only in fiber-like structures, was
detected. At E15.5, staining of nerve fibers in the
mid-brain (MB) was less prominent, but faint
staining in the cerebral cortex (CP) was now
demonstrated. At E16.5 and E18.5, staining was
detected throughout the brain except for a thin
layer of cortical neurons and around the lateral
ventricle that was negative (LV). Stronger staining was detected at regions rich in fibers or where
neurons were not dense; this staining was
detected in glial cells. However it is unclear
whether neurons, axons and dendrites were also
stained.
Amelogenin expression in the developing
peripheral nerve tracts and fibers (Fig. 2a)
At E10.5 almost no nerve fibers were detected.
At E11.5–E16.5 amelogenin expression was
detected in the developing peripheral nerve (NF),
most probably in the glial cells. It is unclear
whether axons and/or dendrites were also stained.
Amelogenin expression in the developing
ganglia and cervical spinal cord (Fig. 2b)
At E10.5 the neural tube was not stained for
amelogenin. At E11.5 amelogenin expression was
not detected in the trigeminal ganglion, or in the
spinal cord. At E12.5 amelogenin staining was
observed in fiber-like structures in the ventral
part of the spinal cord. In sites of the spinal cord
where vertebrae were more organized less amelogenin staining was detected. At E13.5 positive
staining was detected in dorsal spinal cord ganglia,
however, it is not yet clear which type of cells were
stained. At E14.5 the entire spinal cord stained
positively for amelogenin; the staining was further
intensified at E15.5. From E14.5 and thereafter up
to E18.5 the trigeminal ganglion and ganglia at
the vicinity of the tooth germ stained positively.
J. Exp. Zool. (Mol. Dev. Evol.)
Amelogenin expression in the developing
tooth germ (Fig. 2b)
At E13.5 cells in the dental lamina (DL) were
positively stained. At E14.5, in the tooth germ
(TG), specifically in the region of the stellate
reticulum (SR) faint positive staining was also
detected. At E15.5 staining was still detected in
the dental lamina (DL), and was also detected in
the inner enamel epithelium (IEE). At E16.5,
staining was observed in the inner enamel
epithelium (IEE) and stratum intermedium (SI).
Faint staining was detected in the stellate reticulum (SR) and almost no staining in the outer
enamel epithelium (OEE). The oral epithelium
was also stained (not shown) whereas the cervical
loop (CL) was faintly stained. Amelogenin staining
was also detected in developing alveolar bone
trabeculae (Av). At E18.5 the dental papilla (DP),
odontoblasts (Od) and pre-dentin (PD) were
slightly stained, the dentin (D) did not seem to
be stained, followed by very strong purple brown
staining of the developing extracellular enamel
matrix (EM). The ameloblasts (Ab) were stained,
but not at the outmost region of the ameloblast’s
cell nucleus. The stratum intermedium (SI) and
stellate reticulum (SR) surrounding the ameloblasts were only slightly stained. These layers are
covered by the outer enamel epithelium that was
also positively stained.
Amelogenin expression in the developing
cartilage (Fig. 2b)
At E11.5, before cartilage was detected, amelogenin staining was observed in the tissue that will
eventually develop into cartilage (Pc—prechondrocytes) at the base of the skull. At E12.5 some
staining was detected in the developing cartilage,
mainly in surrounding blood vessels but also in
some chondrocytes. At E13.5 the cartilage of the
vertebrae alongside the cervical spinal cord stained
positively. The chondrocytes that were not fully
differentiated did not stain, whereas differentiated
chondrocytes (DC) that underwent hypertrophy
stained positively for amelogenin. At E14.5, prehypertrophic and hypertrophic chondrocytes (WDC)
and the cartilage beneath the perichondrium
stained positively. This was also observed at E15.5
and E16.5, as hypertrophic cartilage (HC) and
perichondrium, as well as blood vessels in various
cranio-facial regions stained positively for amelogenin. At E18.5 both chondrocytes and blood vessels
in the hypertrophic cartilage stained positively.
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
Amelogenin expression in the developing
bone (Fig. 2b)
Bone in the cranio-facial region was first detected
at E13.5. At that developmental stage periosteal
osteoblasts, at the beginning of bone organization,
stained positively. At E14.5, most cell types and not
just osteoblasts in the cranial bones (mainly membranous bone that does not develop from cartilage),
were positively stained. The mandibular alveolar
bone, which is composed of periosteal bone, stained
positively at E14.5 and E15.5. However, only faint
staining was detected in the endochondral mandibular condyle. At E16.5, both endochondral and
membranous bones in the mandible, maxilla and
their surrounding periosteum, stained for amelogenin. This positive staining was also observed at E18.5.
Amelogenin expression in additional
developing tissues (not shown)
From E10.5 through E18.5 the mesenchyme
and connective tissue were positively stained for
amelogenin. On E11.5 amelogenin expression was
detected in loosely packed mesenchymal cells at the
base of the skull. Amelogenin staining at E11.5
was also detected at the region of both, yet vertical,
palatine shelves. The palate continued to be positive
at least until E15.5. The skin and the connective
451
tissue just beneath the skin epithelium
(future dermis) did not stain at E11.5–E16.5. Only
at E18.5 the dermis stained positively for
amelogenin, whereas the epithelium still did not
stain. At E13.5 the connective tissue surrounding
the brain (brain membranes) stained positively. At
E15.5 amelogenin staining was detected in the
salivary glands, which apparently disappeared at
E18.5.
Recruitment of mesenchymal cells by
amelogenin in the developing mandible
Agarose beads containing the recombinant
human amelogenin (rHAM1, long black arrow)
(Taylor et al., 2006), were placed along different
regions of the mandibular mesenchyme of E13.5
mouse embryos. The experimental beads were on
one side of the mandible, whereas the control beads
(long white arrow) were on the contra-lateral side.
The ex-vivo mandible was placed in culture for
one day and then coronal sections were made.
Mesenchymal cells apparently moved toward the
rHAM1 beads and surround the beads (short
arrows), whereas no such cell recruitment could
be seen around the control PBS agarose bead
(Fig. 3).
Fig. 3. Possible recruitment of mesenchymal cells in the developing mandible by amelogenin (rHAM1) beads but not by
control PBS beads. (A, B) rHAM1 beads (long black arrow) one day after bead application on E13.5 mouse embryonic mandibles.
Note the ring of cells surrounding the rHAM1 beads (short arrows). (C) PBS bead (long white arrow). No such phenomenon is
detected around the control bead.
J. Exp. Zool. (Mol. Dev. Evol.)
452
Y. GRUENBAUM-COHEN ET AL.
Recruitment of mesenchymal cells by
amelogenin in the developing incisor
tooth germ
Agarose beads containing rHAM1 or PBS (control) were placed on the mesenchymal region of
the incisor tooth germ of 250 mm frontal sections of
E14.5 mandibles. Changes in DiI distribution
between 0 and 3 days in culture showed movement
(recruitment) of mesenchymal cells toward the
rHAM1 bead (Fig. 4A–D), which eventually
partially covered the bead, whereas no such
movement was observed toward the control PBS
bead (Fig. 4E–H).
DISCUSSION
In this study we focused on the spatio-temporal
expression of amelogenin in different tissues of the
developing embryonic mouse cranio-facial complex. Our results indicate possible signaling and
structural roles for amelogenin during early stages
of embryonic cranio-facial development, in
addition to its known function during enamel
biomineralization. The results clearly show that
the expression of amelogenin in different tissues
is dynamic and depends on the embryonic
developmental stage. The recruitment of mesenchymal cells in the tooth germ and mandible,
at early stages of embryonic development, points
to the functional significance of amelogenin in
these tissues.
Many studies in the field of molecular biology
and biochemistry, have described the function of
amelogenin in structural organization and biomineralization of enamel; in controlling the size,
shape and direction of formation of the enamel
mineral crystallites (Fincham et al., ’94; Du et al.,
2005; Veis, 2005). In the past few years, cell
signaling functions have been attributed to amelogenin low-mass isoforms such as LRAP (A-4/
M59) (Nebgen et al., ’99; Veis, 2003; LacerdaPinheiro et al., 2006a,b; Zeichner-David et al.,
2006; Jegat et al., 2007). The cell surface receptors
for amelogenin (M180 and LRAP), were identified,
and the exact binding regions of amelogenin to its
receptors was deciphered (Shapiro et al., 2007; Zou
et al., 2007). We have recently shown that
recombinant human amelogenin (equivalent to
M180) brought about regeneration of the tooth
supporting mesenchymal tissues: cementum,
PDL and alveolar bone in the dog model. This
regeneration process involved recruitment of
mesenchymal stem cells, also indicating signaling
role(s) for amelogenin (Haze. et al. in submission).
All these studies were performed on postnatal
tissues. Very few detailed studies were carried out
on amelogenin expression in the cranio-facial
complex during prenatal development, and these
Fig. 4. Movement (recruitment) of DiI—labeled mesenchymal cells in the incisor tooth germ region, toward amelogenin
(rHAM1) beads but not toward control PBS bead. Frontal slices through the incisor region of E14.5 mandibles cultured for three
days after addition of beads. Oral and incisor epithelium are outlined in white. The mesenchyme around the incisor cap stage
tooth germs (outlined and marked by ) was labeled with DiI (orange). (A–D) rHAM1 bead at day 0 (A), day 1 (B), day 2 (C), day
3 (D). (A–C) Merged light/dark field image of cultured slice showing DiI label moving toward and around the rHAM1 bead. (D)
Section showing DiI cells associated with the rHAM1 bead. (E–H) Similar slice with a PBS (control) bead at day 0 (A), day 1 (B),
day 2 (C), day 3 (D). (E–G) Merged light/dark field image of cultured slice showing DiI label remaining distinct from the PBS
bead. (H) Section showing DiI cells not associated with the PBS bead.
J. Exp. Zool. (Mol. Dev. Evol.)
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
studies focused mainly on the late stages of
prenatal development when ameloblasts and
odontoblasts had already differentiated, and begun to produce developing enamel and the underlying dentin (Zeichner-David et al., ’97; LacerdaPinheiro et al., 2006b). This is in contrast to the
vast information in the literature on other genes,
their corresponding proteins and the pathways
associated with embryonic cranio-facial and specifically with tooth development, morphogenesis
and differentiation (Tucker and Sharpe, ’99;
Jernvall and Thesleff, 2000; Tucker and Sharpe,
2004; Mitsiadis and Smith, 2006).
In this study we showed that amelogenin mRNA
(Fig. 1) and protein (Fig. 2) are expressed in the
cranio-facial complex from early stages of development (E10.5). Amelogenin protein is expressed
in some tissues of the cranio-facial complex long
before the initiation of tooth formation. The
amelogenin protein was mainly identified in glial
cells, in neural-crest-derived cells and possibly
(but it is still not clear yet) in neurons, as it was
detected in the brain, the retina of the eye,
peripheral ganglia and the peripheral nerve
trunks. In the cranio-facial complex, neural crest
cells also give rise to nonneuronal ecto-mesenchymal tissues such as bone, cartilage and mesenchymal regions of the teeth (Le Douarin et al.,
2007) that were all positive for amelogenin.
Interestingly, the strongest staining for amelogenin was detected in the ameloblasts, extracellular
enamel matrix and the eye lens that are not
thought to be neural crest derived. Other epithelial tissues were not intensely stained (cornea), or
staining was detected at later stages of development (skin, eyelids).
The expression of amelogenin was studied
during mouse embryonic tooth germ development,
from early stages of development, when the
information on the spatio-temporal expression of
amelogenin is rather scarce, to E18.5, when
amelogenin expression in the tooth germ (near
birth) and postnatally is well documented. Amelogenin protein expression was seen already at
E13.5 in the dental lamina, and continued through
embryonic tooth development to E18.5. From
E13.5 up to E16.5 (E17.5 was not analyzed), no
extracellular enamel or dentin is yet formed, and
no biomineralization of enamel or dentin takes
place. Amelogenin, therefore, has different function(s) at these stages than that of regulating the
size, shape and direction of mineral crystal
growth. Late in development and close to birth
(E18.5), amelogenin expression was mainly seen in
453
the mineralizing extracellular enamel matrix and
in the secreting ameloblasts, and also in the
stratum intermedium, pre-dentin and dentin,
and some expression in the dental papilla. The
latter expression pattern, observed by us at E18.5,
has been extensively described, mainly in postnatal mice.
A hint on amelogenin function in the early
stages of tooth and mandible development
emerges from the application of amelogenin beads
on E13.5 mouse embryonic mandibular mesenchyme, which brought about recruitment and cell
movement toward the beads (Fig. 3). This observation was strengthened by the application of
amelogenin beads, in combination with DiI application, on E13.5 and E14.5 embryonic incisor and
first molar (not shown) tooth germs mesenchymal
tissue, respectively. The DiI, which binds to cell
membranes, revealed movement of mesenchymal
cells toward the amelogenin beads, partially covering the beads after 2 and 3 days (Fig. 4). The
amelogenin beads contained the recombinant
human amelogenin protein rHAM1 that is the
human amelogenin isoform corresponding to the
mouse isoform M180 (which contains exons 1–7,
lacking exon 4). No such recruitment of mesenchymal cells was detected toward the control PBS
bead. As amelogenin is endogenously expressed in
these mesenchymal and tooth germ tissues at the
days rHAM1 beads were applied (Fig. 2), these
experiments represent over-expression and not
ectopic expression. The observed cell recruitment
suggests a signaling function for amelogenin. This
is in line with the accumulating data on the
signaling function of amelogenin, including our
recent data (Haze et al. in submission). Other
studies in which low molecular mass amelogenin
isoforms produced ectopically chondrogenic and
osteogenic-like tissue and caused ameloblasts and
odontoblasts differentiation suggested prenatal
and postnatal signaling effects for the different
amelogenin isoforms (Nebgen et al., ’99; Veis,
2003; Lacerda-Pinheiro et al., 2006a,b; Jegat et al.,
2007) (also see introduction on possible signaling
activity of amelogenin).
As was previously described, amelogenin, which
is a structural protein during enamel bio-mineralization, regulates the shape, size and direction of
mineral crystal growth. The patterns of amelogenin expression in lens fibers, in brain fibers and
in nerve trunk fibers suggest a possible role for
amelogenin in elongating structures within some
developing cells. It is tempting to speculate that
the model of elongated amelogenin nanospheres
J. Exp. Zool. (Mol. Dev. Evol.)
454
Y. GRUENBAUM-COHEN ET AL.
(Du et al., 2005) might be somehow relevant to its
role in developing fibers, but other mechanisms
are also feasible. In the eye, amelogenin is mainly
expressed in the posterior lens epithelium cells
that elongate up to several hundred times during
the process of differentiation into fiber cells. In the
nervous tissues; brain, optic nerve and nerve
trunks, amelogenin expression was mostly localized to fiber like structures. Glial and mesenchymal cells are known to surround nerve fibers,
whether they are axons or dendrites. Several lines
of evidence indicate that amelogenin is mainly
expressed by the glial cells; (i) virtually no staining
for amelogenin was detected in the cortex that is
mainly composed of neuroblasts, whereas the subcortical regions, where many more glial cells exist,
was positively stained for amelogenin. (ii) Amelogenin was detected in postnatal glial cells surrounding brain neurons but not in the neurons
themselves (Deutsch et al., 2006). A major role of
glial cells during development is to support and
direct the growth and elongation of neurons.
In 2001, the phenotype of the amelogenin
knockout (null) mouse was published. The only
phenotype described at that time was of abnormal
enamel formation; the teeth of the amelogenin
null mouse expressed a hypoplastic enamel phenotype with reduced enamel thickness (Gibson
et al., 2001). As often happens, additional, different phenotypes of the amelogenin null mouse were
later described. A progressive deterioration of
cementum (a mineralized tissue covering the tooth
root surface) was observed in the amelogenin null
mouse. The defects in cementum were characterized by increased presence of osteoclasts, and were
also associated with an increased expression of
receptor activator of nuclear factor-kB ligand
(RANKL) near the cementum, suggesting that
amelogenin may play a role in osteoclastogenesis
through the RANKL/RANK mediated pathway
(Hatakeyama et al., 2003). In 2006, an additional
phenotypic defect was published: the weight of the
null mouse was significantly reduced compared
with the wild type (Li et al., 2006). No reports
have been made on phenotypes in other craniofacial tissues and body organs. This is not
surprising, as only at 2006 amelogenin expression
in other mesenchymal mineralizing tissues, such
as alveolar bone, long bone and cartilage, and in
cranio-facial soft tissues such as brain and salivary
gland were published (Deutsch et al., 2006; Haze
et al., 2007). Our recent findings of amelogenin
expression in active alveolar bone regions (Haze et
al. in submission), in epiphyseal growth plate of
J. Exp. Zool. (Mol. Dev. Evol.)
long bone, its expression in osteoblasts, osteoclasts
and osteocytes, as well as the periosteum suggest
that amelogenin is active in bone formation and
remodeling (Haze et al., 2007). Indeed, as was
described above, we found that the recombinant
amelogenin brought about regeneration of the
tooth supporting tissues via recruitment of mesenchymal stem cells (Haze et al. in submission).
In this study it is evident that the expression of
amelogenin in different cranio-facial tissues is
dynamic and depends on embryonic stage. Our
results suggest that additional phenotypes might
be revealed when cranio-facial and body tissues in
which amelogenin was found to be expressed in
the wild type, will be studied in the null mouse.
However, it is possible that different compensation pathways lead to normal phenotype in other
tissues of the knockout mice.
This study suggests that amelogenin could have
structural and signaling roles in the development
of various tissues of the cranio-facial complex
including the developing tooth germ, and also in
other body organs. The results of this study open
new horizons as to the function(s) of amelogenin
in different tissues during embryonic cranio-facial
development. Naturally, there are numerous
questions that can be asked and many studies
that can be conducted to reveal the molecular
mechanisms and pathways with which amelogenin
is associated.
MATERIALS AND METHODS
Animals
Embryos from CD-1 mice aged E10.5-E18.5,
were used in this study. Embryos from six
pregnant mice were used for each age. All
experiments were approved by the Animal Care
Ethical Committee of the Faculty of Medicine, The
Hebrew University of Jerusalem.
Preparation of embryonic tissues
Pregnant mice were sacrificed, the embryos
were immediately collected and the heads
were removed for further analyses. For histology
and immunohisochemistry, the heads were
immediately fixed in 4% Para-Formaldehyde
(PFA) over-night at 41C. The tissues were then
washed several times in PBS, and dehydrated in
increasing ethanol concentrations of 30, 50, 70, 80,
85, 90, 95 and 100%. The tissues were then
immersed in Histoclear/Xylene, embedded in
paraffin and frontally sectioned (5 mm) from the
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
nose in an anterior–posterior direction. For
mRNA and protein analysis heads were immediately immersed in TRI-REAGENT (MRC, Cincinnati, OH).
RNA isolation and RT-PCR
Total RNA was extracted by homogenizing the
cranio-facial complexes of E10.5–E17.5 in TRIREAGENT (MRC). RNA isolation was performed
using the TRI-REAGENT standard protocol. All
total RNA extracts were subjected to DNase
treatment (DNA free, Ambion, Austin, TX) to
eliminate any possible DNA contamination. Total
RNA concentration was determined using the
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Total RNA
was subjected to reverse transcription according to
the manufacturer’s protocol (Superscript RNase
H—Reverse Transcriptase kit, Invitrogene, Carlsbad, CA). RT and PCR amplification were performed using primers designed according to the
mouse amelogenin sequence (Gibson et al., 2001),
Forward, DD391: 50 -AGA AAC TCA CTG AGC
ATA CAC-30 , and reverse, DD390, 50 -GAT GGA
GGG ATG TTT GGC TG-30 . PCR products were
extracted from 2% agarose gels using Qiaquick gel
extraction kit (Qiagen, Valencia, CA) and sequenced at the Center for Genomic Technologies,
Hebrew University (Jerusalem, Israel).
Indirect immunohistochemistry
Slides were deparaffinized, hydrated, rinsed in
PBS and endogenous peroxidase activity was
blocked by 3% H2O2 (diluted in methanol) for
10 min. Slides were blocked in nonimmune goat
serum for 20 min (Histostain-SP kit, Zymed
laboratories Inc., San Francisco, CA), followed by
over-night incubation of the primary antibody
(diluted in PBS) at 41C in a humidified chamber.
The first antibodies used were: (a) 270 Polyclonal
rabbit antibody, raised against amelogenin
N-terminus (MPLPPHPG) (identical in mouse,
human, etc.) and diluted in PBS to 1/500–1/1000.
(b) 859 polyclonal rabbit antibody raised against
rat amelogenin. The specificity of the antibodies
was previously determined (Haze et al. in submission), by subjecting the antibodies to sections
obtained from the amelogenin knockout mouse
(Gibson et al., 2001) mandible. No staining for
amelogenin was obtained in the mandible, including, among others, the ameloblasts and enamel.
On the other hand, using the same conditions,
some of the corresponding wild type tissues,
455
including the ameloblasts and enamel showed
strong staining for amelogenin.
After rinsing, slides were treated according to
the Histostain-SP kit protocol (Zymed laboratories
inc.). Negative controls included PBS in place of
the first antibody. For better viewing of the
histology of the tissue, the slides were stained
with hematoxylin (Pioneer Research Chemicals,
Colchester, Essex blue staining). All slides were
examined by Axioskop (Zeiss, Göttingen, Germany). The pictures were taken using Coolpix
990 digital camera (Nikon, Tokyo, Japan), and
ProgRes C10 (Jenoptik, Jena, Germany).
Preparation and culturing of mouse
embryonic mandibles
Freshly harvested (13.5 day) embryo heads were
placed in Dulbeco’s modified Eagle’s medium
(DMEM) (with L-glutamatmine), containing
20 units/mL penicillin/streptomycin (Biological Industries, Beit Ha’emeck, Israel; Sigma-Aldrich,
Rehovot,Israel). The mandibles were dissected
from the cranio-facial complex by using watchmaker’s forceps (FST, Vancouver, Canada) and
27-gauge sterile needles (Sherwood Medical Industries, Athy, Ireland). The dissected mandibles
were then placed on a 0.1 mm Millipore filter
(Millipore Southampton) coated with Matrigel
(BD Biosciences, San Jose, CA), and then covered
with Matrigel. The filter paper with the mandible
was then placed on a 35 mm triangle stainless steel
metal grid, with 0.25 mm diameter mesh wire
(Goodfellows, Cambridge), placed in Falcon 60 mm
Center-well Organ Culture dishes (BD Biosciencse, San Jose, CA). The center well was filled
with DMEM (with L-glutamatmine) and 20 u/mL
penicillin/streptomycin, up to the mesh surface,
and the narrow well, surrounding the center well,
was filled with double distilled sterile water. The
cultures were grown in a standard incubator at
371C with an atmosphere of 5% CO2. After
incubation in culture for one day, explants were
washed in ice-cold methanol for 2 min and then
fixed in 4% paraformaldehyde for 2 hr at room
temperature. The explants were then embedded in
paraffin, sectioned and counterstained with eosin
for histology.
Bead preparation and placement on mouse
embryonic mandible explant cultures
Affi-gel agarose beads (Bio-Rad Laboratories,
Hercules, CA) (75–100 mm) were separated by size
under stereomicroscope, washed thoroughly in
J. Exp. Zool. (Mol. Dev. Evol.)
456
Y. GRUENBAUM-COHEN ET AL.
PBS, air dried and suspended in rHAM1 (Taylor
et al., 2006) (1 mg/mL) dissolved in 0.05 M acetic
acid solution, at 371C for 30 min. Before use, beads
were washed in PBS (neutralizing the acid), and
the beads were then placed on E13.5 mandibular
explant, in the incisor region, the molar region and
on the mandible diastema region (experimental
beads). Control beads were prepared in a similar
manner by using only PBS, and were placed on the
contra-lateral side of the mandible in similar
regions as the experimental beads. Mouse embryonic mandible explant cultures containing Affigel beads were grown for one day, as described
below
Preparation of 250 lm thick frontal
sections of mouse embryonic mandibles
for DiI studies
E13.5 and E14.5 mouse embryonic mandibles
were frontally dissected into 250 mm thick sections, using Mcllwain Tissue Chopper (Science
Products GmbH, Hofheim, Germany) as described
in Matalova et al., 2005. Briefly, sections containing first molars, or incisors, were selected under
the microscope in medium. Affi-gel beads (control
and experimental) were placed on the tooth germ
mesenchymal region, and CellTrackerTM CM-Dil
(Molecular probes, Invitrogen, Eugene, OR) was
injected into the mesenchymal cells in the vicinity
of the beads using a mouth pipette. Slices were
placed on a 0.4 mm FalconTM cell culture inserts
(Falcon, BD Labware, Franklin Lakes,NJ). The
sliced tissue was then covered with Matrigel (BD
Biosciences), and cultured as was described above
for the mandibular explant for up to 3 days. The
cultures were photographed every 24 hr using a
Leica dissecting microscope under either bright
field, dark field or both (for superimposition) to
monitor the DiI at 0, 1 and 2 days. Cultures were
fixed at day 2 and embedded in wax for sectioning.
After sectioning the localization of DiI was photographed using a Zeiss Fluorescence compound
microscope. Sections were then stained for histology and re-photographed. The DiI label is fixable
but lost after staining for histology.
ACKNOWLEDGMENTS
The authors thank Dr. Carolyn W. Gibson,
University of Pennsylvania, Philadelphia, PA, for
her generous gift of the 270 and 859 amelogenin
antibodies. We are grateful to Dr. Shahar Frenkel,
Hadassah-Hebrew University Medical Center,
Jerusalem, Israel, for the useful comments
J. Exp. Zool. (Mol. Dev. Evol.)
on eye development. The authors are grateful for
the support of the COST Action B23 for funding
short-term missions.
LITERATURE CITED
Baba O, Takahashi N, Terashima T, Li W, Denbesten PK,
Takano Y. 2002. Expression of alternatively spliced rna
transcripts of amelogenin gene exons 8 and 9 and its end
products in the rat incisor. J Histochem Cytochem
50:1229–1236.
Deutsch D, Catalano-sherman J, Dafni L, David S, Palmon A.
1995. Enamel matrix proteins and ameloblast biology.
Connect Tissue Res 32:97–107.
Deutsch D, Haze-Filderman A, Blumenfeld A, Dafni L,
Leiser Y, Shay B, Gruenbaum-Cohen Y, Rosenfeld E,
Fermon E, Zimmermann B, Hagewald S, Bernimoulin JP,
Taylor AL. 2006. Amelogenin, a major structural protein in
mineralizing enamel is also expressed in soft tissues: brain
and cells of the hematopoietic system. Eur J Oral Sci 114
(Suppl 1):183–189; discussion 201–202, 381.
Diekwisch T, David, S, Bringas Pjr, Santos V, Slavkin HC.
1993. Antisense inhibition of amel translation demonstrates
supramolecular controls for enamel hap crystal growth
during embryonic mouse molar development. Development
117:471–482.
Du C, Falini G, Fermani S, Abbott C, Moradian-Oldak J. 2005.
Supramolecular assembly of amelogenin nanospheres into
birefringent microribbons. Science 307:1450–1454.
Fincham AG, Bessem CC, Lau EC, Pavlova Z, Shuler C,
Slavkin HC, Snead ML. 1991. Human developing enamel
proteins exhibit a sex-linked dimorphism. Calcif Tissue Int
48:288–290.
Fincham AG, Moradian-Oldak J, Simmer JP, Sarte P, Lau EC,
Diekwisch T, Slavkin HC. 1994. Self-assembly of a recombinant amelogenin protein generates supramolecular structures. J Struct Biol 112:103–109.
Fong CD, Hammarstrom L. 2000. Expression of amelin and
amelogenin in epithelial root sheath remnants of fully
formed rat molars. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod 90:218–223.
Gibson CW, Yuan ZA, Hall B, Longenecker G, Chen E,
Thyagarajan T, Sreenath T, Wright JT, Decker S,
Piddington R, Harrison G, Kulkarni AB. 2001. Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 276:31871–31875.
Hammarstrom L, Heijl L, Gestrelius S. 1997. Periodontal
regeneration in a buccal dehiscence model in monkeys after
application of enamel matrix proteins. J Clin Periodontol
24:669–677.
Hart PS, Vlaservich AC, Hart TC, Wright JT. 2000. Polymorphism (g2035c4t) in the amelogenin gene. Hum Mutat
15:298.
Hatakeyama J, Sreenath T, Hatakeyama Y, Thyagarajan T,
Shum L, Gibson CW, Wright JT, Kulkarni AB. 2003. The
receptor activator of nuclear factor-kappa b ligand-mediated
osteoclastogenic pathway is elevated in amelogenin-null
mice. J Biol Chem 278:35743–35748.
Haze A, Taylor AL, Blumenfeld A, Rosenfeld E, Leiser Y,
Dafni L, Shay B, Gruenbaum-Cohen Y, Fermon E,
Haegewald S, Bernimoulin JP, Deutsch D. 2007. Amelogenin expression in long bone and cartilage cells and in
bone marrow progenitor cells. Anat Rec (Hoboken)
290:455–460.
AMELOGENIN IN CRANIO-FACIAL AND TOOTH DEVELOPMENT
Hu B, Nadiri A, Kuchler-Bopp S, Perrin-Schmitt F, Peters H,
Lesot H. 2006. Tissue engineering of tooth crown, root, and
periodontium. Tissue Eng 12:2069–2075.
Janones DS, Massa LF, Arana-Chavez VE. 2005. Immunocytochemical examination of the presence of amelogenin
during the root development of rat molars. Arch Oral Biol
50:527–532.
Jegat N, Septier D, Veis A, Poliard A, Goldberg M. 2007.
Short-term effects of amelogenin gene splice products a14
and a 4 implanted in the exposed rat molar pulp. Head
Face Med 3:40.
Jernvall J, Thesleff I. 2000. Reiterative signaling and
patterning during mammalian tooth morphogenesis. Mech
Dev 92:19–29.
Lacerda-Pinheiro S, Jegat N, Septier D, Priam F, Bonnefoix
M, Bitard J, Kellermann O, Tompkins K, Veis A,
Goldberg M, Poliard A et al. 2006a. Early in vivo and in
vitro effects of amelogenin gene splice products on pulp
cells. Eur J Oral Sci 114:232–238; discussion 254–256,
381–382.
Lacerda-Pinheiro S, Septier D, Tompkins K, Veis A,
Goldberg M, Chardin H. 2006b. Amelogenin gene splice
products a14 and a-4 implanted in soft tissue determine the
reorientation of cd45-positive cells to an osteo-chondrogenic
lineage. J Biomed Mater Res A 79:1015–1022.
Lau EC, Mohandas TK, Shapiro LJ, Slavkin HC, Snead ML.
1989. Human and mouse amelogenin gene loci are on the
sex chromosomes. Genomics 4:162–168.
Le Douarin NM, Brito JM, Creuzet S. 2007. Role of the neural
crest in face and brain development. Brain Res Rev
55:237–247.
Li W, Mathews C, Gao C, Denbesten PK. 1998. Identification
of two additional exons at the 30 end of the amelogenin gene.
Arch Oral Biol 43:497–504.
Li Y, Yuan ZA, Aragon MA, Kulkarni AB, Gibson CW. 2006.
Comparison of body weight and gene expression in amelogenin null and wild-type mice. Eur J Oral Sci 114:190–193;
discussion 201–202, 381.
Lyngstadaas SP, Risnes S, Sproat BS, Thrane PS, Prydz HP.
1995. A synthetic, chemically modified ribozyme eliminates
amelogenin, the major translation product in developing
mouse enamel in vivo. EMBO J 14:5224–5229.
Matalova E, Antonarakis GS, Sharpe PT, Tucker AS, 2005.
Cell lineage of primary and secondary enamel. Dev Dyn
233:754–759.
Mitsiadis TA, Smith MM. 2006. How do genes make teeth to
order through development? J Exp Zoolog B Mol Dev Evol
306:177–182.
Nebgen DR, Inoue H, Sabsay B, Wei K, Ho CS, Veis A. 1999.
Identification of the chondrogenic-inducing activity from
bovine dentin (bcia) as a low-molecular-mass amelogenin
polypeptide. J Dent Res 78:1484–1494.
Oida S, Nagano T, Yamakoshi Y, Ando H, Yamada M,
Fukae M. 2002. Amelogenin gene expression in porcine
odontoblasts. J Dent Res 81:103–108.
Papagerakis P, Macdougall M, Hotton, D, Bailleul-Forestier I,
Oboeuf M, Berdal A. 2003. Expression of amelogenin in
odontoblasts. Bone 32:228–240.
457
Papagerakis P, Ibarra JM, Inozentseva N, Denbesten P,
macdougall M. 2005. Mouse amelogenin exons 8 and 9:
sequence analysis and protein distribution. J Dent Res
84:613–617.
Robinson C, Kirkham J, Weatherell JA, Richards A,
Josephsen K, Fejerskov O. 1988. Mineral and protein
concentrations in enamel of the developing permanent
porcine dentition. Caries Res 22:321–326.
Robinson C, Brookes SJ, Shore RC, Kirkham J. 1998. The
developing enamel matrix: Nature and function. Eur J Oral
Sci 106:282–291.
Salido EC, Yen PH, Koprivnikar K, Yu LC, Shapiro LJ. 1992.
The human enamel protein gene amelogenin is expressed
from both the x and the y chromosomes. Am J Hum Genet
50:303–316.
Shapiro JL, Wen X, Okamoto CT, Wang HJ, Lyngstadaas SP,
Goldberg M, Snead ML, Paine ML. 2007. Cellular uptake of
amelogenin, and its localization to cd63, and lamp1-positive
vesicles. Cell Mol Life Sci 64:244–256.
Simmer JP, Fincham AG. 1995. Molecular mechanisms
of dental enamel formation. Crit Rev Oral Biol Med
6:84–108.
Simmer JP, Hu JC. 2002. Expression, structure, and function
of enamel proteinases. Connect Tissue Res 43:441–449.
Taylor AL, Haze-Filderman A, Blumenfeld A, Shay B, Dafni L,
Rosenfeld E, Leiser Y, Fermon E, Gruenbaum-Cohen Y,
Deutsch D. 2006. High yield of biologically active recombinant human amelogenin using the baculovirus expression
system. Protein Expr Purif 45:43–53.
Termine JD, Belcourt AB, Christner PJ, Conn KM,
Nylen MU. 1980. Properties of dissociatively extracted
fetal tooth matrix proteins. I. Principal molecular
species in developing bovine enamel. J Biol Chem
255:9760–9768.
Tucker A, Sharpe P. 2004. The cutting-edge of mammalian
development; how the embryo makes teeth. Nat Rev Genet
5:499–508.
Tucker AS, Sharpe PT. 1999. Molecular genetics of tooth
morphogenesis and patterning: the right shape in the right
place. J Dent Res 78:826–834.
Veis A. 2003. Amelogenin gene splice products: potential
signaling molecules. Cell Mol Life Sci 60:38–55.
Veis A. 2005. A window on biomineralization. Science
307:1419–1420.
Zeichner-David M, Vo H, Tan H, Diekwisch T, Berman B,
Thiemann F, Alcocer MD, Hsu P, Wang T, Eyna J, Caton J,
Slavkin HC, MacDougall M, 1997. Timing of the expression
of enamel gene products during mouse tooth development.
Int J Dev Biol 41:27–38.
Zeichner-David M, Chen LS, Hsu Z, Reyna J, Caton J,
Bringas P. 2006. Amelogenin and ameloblastin show
growth-factor like activity in periodontal ligament
cells. Eur J Oral Sci 114:244–253; discussion 254–256,
381–382.
Zou Y, Wang H, Shapiro JL, Okamoto CT, Brookes SJ,
Lyngstadaas SP, Snead ML, Paine ML. 2007. Determination
of protein regions responsible for interactions of amelogenin
with cd63 and lamp1. Biochem J 408:347–354.
J. Exp. Zool. (Mol. Dev. Evol.)